Mast Therapeutics, Inc. MSTX-Financial and Strategic SWOT Analysis Review

Mast Therapeutics, Inc. MSTX-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH66512FSA
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Mast Therapeutics, Inc. (MSTX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mast Therapeutics, Inc. (Mast Therapeutics) is a biopharmaceutical company, which develops clinical-stage therapies for serious or life-threatening diseases. The company develops therapies for sickle cell disease, a chronic, genetic disorder for rare or orphan disease. The company's lead product MST-188 (also known as vepoloxamer) is being developed for the treatment of of vaso-occlusive crisis in patients with sickle cell disease. Its pipeline includes development programs in the areas of adjunctive thrombolytic therapy, heart failure, resuscitation and major trauma. The company develops MST-188 utilizing its proprietary technology molecular adhesion and sealant technology (MAST). The company is headquartered in San Diego, California, the US.

Mast Therapeutics, Inc. Key Recent Developments

May 06, 2016: Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights

Mar 14, 2016: Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results

Jan 07, 2016: Mast Therapeutics Provides Business Update

Nov 12, 2015: Mast Therapeutics Reports Third Quarter 2015 Financial Results

Nov 09, 2015: Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Mast Therapeutics, Inc.-Key Facts 6

Mast Therapeutics, Inc.-Key Employees 7

Mast Therapeutics, Inc.-Key Employee Biographies 8

Mast Therapeutics, Inc.-Major Products and Services 9

Mast Therapeutics, Inc.-Pharmaceutical Pipeline Products Data 10

Mast Therapeutics, Inc., Pipeline Products by Therapy Area 10

Mast Therapeutics, Inc., Pipeline Products by Development Phase 11

Mast Therapeutics, Inc.-History 13

Mast Therapeutics, Inc.-Company Statement 16

Mast Therapeutics, Inc.-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Section 2-Company Analysis 21

Mast Therapeutics, Inc.-Business Description 21

Mast Therapeutics, Inc.-Corporate Strategy 22

Mast Therapeutics, Inc.-SWOT Analysis 23

SWOT Analysis-Overview 23

Mast Therapeutics, Inc.-Strengths 23

Strength-Sturdy R&D Activities 23

Strength-Proprietary Technology: Molecular Adhesion and Sealant Technology (MAST) 23

Mast Therapeutics, Inc.-Weaknesses 24

Weakness-Lack of Marketed Products 24

Weakness-Higher Cost Structure 24

Mast Therapeutics, Inc.-Opportunities 25

Opportunity-Rising Healthcare Expenditure in the US 25

Opportunity-Positive Outlook: Sickle cell disease, Arterial Disease and Heart Failure 25

Opportunity-Orphan Drug Designation: MS-188 25

Mast Therapeutics, Inc.-Threats 26

Threat-Competitive Pressures 26

Threat-Stringent Government Regulations 26

Threat-Uncertain R&D Outcomes 26

Threat-Reliance on Third Party Manufacturers 26

Mast Therapeutics, Inc.-Key Competitors 27

Section 3-Company Financial Ratios 28

Financial Ratios-Capital Market Ratios 28

Financial Ratios-Annual Ratios 29

Performance Chart 30

Financial Performance 30

Financial Ratios-Interim Ratios 31

Financial Ratios-Ratio Charts 32

Section 4-Company's Lifesciences Financial Deals and Alliances 33

Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 34

Mast Therapeutics, Inc., Recent Deals Summary 35

Section 5-Company's Recent Developments 36

May 06, 2016: Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights 36

Mar 14, 2016: Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results 37

Jan 07, 2016: Mast Therapeutics Provides Business Update 38

Nov 12, 2015: Mast Therapeutics Reports Third Quarter 2015 Financial Results 39

Nov 09, 2015: Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors 40

Nov 02, 2015: Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors 41

Oct 13, 2015: BASF to Develop a High Purity Poloxamer for Mast Therapeutics 42

Aug 12, 2015: Mast Therapeutics Reports Second Quarter 2015 Financial Results 43

May 28, 2015: Mast Therapeutics Announces Change In Board Of Directors 45

May 11, 2015: Mast Therapeutics Reports First Quarter 2015 Financial Results 46

Section 6-Appendix 47

Methodology 47

Ratio Definitions 47

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Mast Therapeutics, Inc., Pipeline Products by Therapy Area 10

Mast Therapeutics, Inc., Pipeline Products by Development Phase 11

Mast Therapeutics, Inc., Performance Chart (2011-2015) 30

Mast Therapeutics, Inc., Ratio Charts 32

Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 34

List of Tables

Mast Therapeutics, Inc., Key Facts 6

Mast Therapeutics, Inc., Key Employees 7

Mast Therapeutics, Inc., Key Employee Biographies 8

Mast Therapeutics, Inc., Major Products and Services 9

Mast Therapeutics, Inc., Number of Pipeline Products by Therapy Area 10

Mast Therapeutics, Inc., Number of Pipeline Products by Development Stage 11

Mast Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase 12

Mast Therapeutics, Inc., History 13

Mast Therapeutics, Inc., Subsidiaries 20

Mast Therapeutics, Inc., Key Competitors 27

Mast Therapeutics, Inc., Ratios based on current share price 28

Mast Therapeutics, Inc., Annual Ratios 29

Mast Therapeutics, Inc., Interim Ratios 31

Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 34

Mast Therapeutics, Inc., Recent Deals Summary 35

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

MediciNova, Inc.

Astex Pharmaceuticals, Inc.

Apotex Inc.

Mast Therapeutics, Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8045
Site License
USD 250 INR 16090
Corporate User License
USD 375 INR 24135

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com